Effects of lysosomotropic agents, cytochalasin B and colchicine on the "down-regulation" of prolactin receptors in mammary gland explants

Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase

Ubiquitin-dependent degradation of hormone receptors is emerging as a key mechanism that regulates the magnitude and duration of hormonal effects on cells and tissues. The pituitary hormone prolactin (PRL) is involved in regulating cell differentiation, proliferation, and survival. PRL engages its receptor (PRLR) to initiate various signaling cascades, including the phosphorylation and activation of Stat5. We found that PRL promotes interaction between PRLR and the F-box protein beta-TrCP2, which functions as a substrate recognition subunit of the SCF(beta-TrCP) E3 ubiquitin ligase. This interaction requires PRLR phosphorylation and the integrity of serine 349 within a conserved motif, which is similar to conserved motifs present in other substrates of SCF(beta-TrCP). The PRLR(S349A) mutant is resistant to ubiquitination and is more stable than its wild-type counterpart. Phosphorylated PRLR undergoes ubiquitination by SCF(beta-TrCP) in vitro. Knockdown of beta-TrCP expression inhibits the ubiquitination and degradation of PRLR and promotes PRL-dependent phosphorylation of Stat5 as well as Stat5-dependent transcription in cells. Furthermore, the activation of Stat5 and the stimulation of cell growth by PRL are augmented in cells expressing the PRLR(S349A) mutant. These data indicate that PRLR is a novel SCF(beta-TrCP) substrate and implicate beta-TrCP as an important negative regulator of PRL signaling and cellular responses to this hormone.

Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells

Prolactin (PRL) and estrogen act synergistically to increase mammary gland growth, development, and differentiation. Based on their roles in the normal gland, these hormones have been studied to determine their interactions in the development and progression of breast cancer. However, most studies have evaluated only endocrine PRL and did not take into account the recent discovery that PRL is synthesized by human mammary cells, permitting autocrine/paracrine activity. To examine the effects of this endogenous PRL, we engineered MCF7 cells to inducibly overexpress human prolactin (hPRL). Using this Tet-On MCF7hPRL cell line, we studied effects on cell growth, PRLR, ER alpha, and PgR levels, and estrogen target genes. Induced endogenous hPRL, but not exogenous hPRL, increased ER alpha levels as well as estrogen responsiveness in these cells, suggesting that effects on breast cancer development and progression by estrogen may be amplified by cross-regulation of ER alpha levels by endogenous hPRL. The long PRLR isoform was also upregulated by endogenous, but not exogenous PRL. This model will allow investigation of endogenous hPRL in mammary epithelial cells and will enable further dissection of PRL effects on other hormone signaling pathways to determine the role of PRL in breast cancer.

The role of prolactin in mammary carcinoma

The contribution of prolactin (PRL) to the pathogenesis and progression of human breast cancer at the cellular, transgenic, and epidemiological levels is increasingly appreciated. Acting at the endocrine and autocrine/paracrine levels, PRL functions to stimulate the growth and motility of human breast cancer cells. The actions of this ligand are mediated by at least six recognized PRL receptor isoforms found on, or secreted by, human breast epithelium. The PRL/PRL receptor complex associates with and activates several signaling networks that are shared with other members of the cytokine receptor superfamily. Coupled with the recently identified intranuclear function of PRL, these networks are integrated into the in vitro and in vivo actions induced by ligand. These findings indicate that antagonists of PRL/PRL receptor interaction or PRL receptor-associated signal transduction may be of considerable utility in the treatment of human breast cancer.

Growth hormone-binding protein in the goat: characterization, evolution under exogenous growth hormone treatment, and correlation with liver growth hormone receptor levels

This report describes the identification and characterization of a specific, high-affinity growth hormone-binding protein (GHBP) in lactating goat serum. Serum samples were incubated with [125I]human GH as ligand and in the absence or in the presence of bovine GH as competitor. GH-GHBP complex formation was performed by high-performance liquid chromatography, and the radioactivity was recorded on-line with a Berthold LB detector connected to a computer. The results showed that a serum protein was able to bind specifically to human GH and bovine GH but not to ovine prolactin. Scatchard plots indicated an affinity constant of 4.5 x 10(8) M-1 and a maximum binding capacity of 4.8 x 10(-10) mol/l. In addition, we conducted a 4-wk study to determine the effects of recombinant bovine GH administration on milk production in lactating goats. The effects of recombinant bovine GH treatment on milk production and on the regulation of GHBP and hepatic GH receptor levels were studied. As expected, recombinant bovine GH injected daily increased yields of milk, fat, protein (40, 61, and 40%, respectively), and circulating insulin-like growth factor 1 concentrations compared with controls. During the pretreatment and treatment periods, the control goats exhibited a constant amount of GHBP in serum. No consistent effect of GH treatment on GHBP level was observed. The binding of [125I]bovine GH to hepatic microsomal membranes of GH-treated goats was significantly decreased compared with that of control goats. After MgCl2 desaturation of membranes, the results demonstrated that the down-regulation of GH hepatic receptors, observed for the treated goat group, was induced by receptor occupancy without modification of binding affinity. The GH receptor gene expression, analyzed by slot blot and hybridization with an [alpha-32P]GH receptor cDNA probe, was not modified by the GH treatment. In lactating goats, the galactopoietic effect of exogenous GH involved a hepatic receptor occupancy. The individual concentration of GHBP in serum cannot explain the individual variations of responses to GH treatment in goats.

Osmotic shock of cultured primary mammary cells amplifies the hormonal induction of casein gene expression

Primary cells from rabbit mammary gland cultured on floating collagen were transfected with various plasmids in different conditions. Conventional transfection methods using DEAE-dextran or calcium phosphate followed by an osmotic shock with dimethyl sulphoxide (DMSO), polyethylene glycol (PEG) or glycerol did not prevent lactogenic hormones to induce casein synthesis. On the contrary and unexpectedly, casein synthesis was markedly stimulated by transfection. This amplification was obtained as well with DMSO, PEG and glycerol alone or in the presence of DEAE-dextran, calcium phosphate or DNA. None of these compounds induced casein synthesis in the absence of prolactin. A shock by DMSO also amplified the accumulation of beta-casein mRNA in the presence of prolactin. These results show for the first time that primary cultured mammary cells can be efficiently transfected and still keep their capacity to respond to lactogenic hormones. They also indicate that the short osmotic shocks conventionally used in transfection have a potent long-term stimulatory effect on casein gene expression, which is mediated through an unknown mechanism.

Comparison of insulin-like growth factor 1 and insulin effects on prolactin-induced lactogenesis in the rabbit mammary gland in vitro

In organ culture of pregnant rabbit mammary gland, a low casein synthesis occurs with prolactin (PRL) alone. Insulin markedly potentiates the effect of PRL. Only pharmacological concentrations of insulin (5 micrograms/ml) exert the maximal enhancement, suggesting a possible interaction with the insulin-like growth factor 1 (IGF1) receptor. The presence of IGF1 and insulin binding sites was analyzed and the biological effects of both peptides were compared. Binding of iodinated human IGF1 or porcine insulin to mammary microsomes prepared from mid-pregnant rabbits revealed distinct high affinity binding sites for both peptides (Kd approximately 2 nM). In rabbit mammary explants, we confirmed that only non-physiological concentrations of insulin (greater than or equal to 100 ng/ml) exerted a significant stimulation of the PRL effect. Surprisingly, IGF1 was not found to be more potent than insulin on a molar basis, which did not provide evidence for the exclusive involvement of the IGF1 receptor. Near-physiological concentrations of IGF1 (approximately 100 ng/ml), however, exerted a significant enhancement which suggested a possible action for IGF1 on PRL-induced lactogenesis in vivo.

Purification of prolactin receptors from sow mammary gland and polyclonal antibody production

After solubilization with Triton X-100 or 3-[(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate (CHAPS), prolactin receptors from mammary crude membranes of primiparous lactating sows (pretreated with bromocriptine) have been purified by affinity chromatography using ovine prolactin or a monoclonal antibody against rabbit prolactin receptor. Comparative analysis of these two methods of purification demonstrated that use of an immunoaffinity step allowed a great improvement of receptor yield (40%) compared to the hormone affinity method (10%). In addition, partially purified fractions obtained by immunoaffinity appeared more homogeneous and had much higher specific activity. Affinity labelling of prolactin receptors from crude membranes or solubilized extracts with iodinated ovine prolactin, followed by electrophoretic analysis (SDS-PAGE) and autoradiography, revealed one binding unit of approximately 45 kDa. When partially purified receptor preparations were labelled with 125I, submitted to an additional affinity chromatography and analyzed by SDS-PAGE, prolactin receptors appeared as a single form having a molecular weight of 42-45 kDa, which is not associated with itself or other subunits by disulfide linkages. Partially purified fractions were used to produce anti-prolactin receptor serum from goats. These polyclonal antibodies were able to completely inhibit the binding of lactogenic hormones in sow and rabbit mammary membranes. They were also able to recognize hormone-receptor complexes, but more specifically in sow mammary gland. These antisera could inhibit prolactin binding to its receptors in several organs of various species, suggesting that prolactin receptors shared numerous antigenic similarities between species and particularly between sow and rabbit. These similarities appeared to be located essentially on the part of the molecule more specifically involved in the recognition of the hormone.

Characterization of a prolactin-daunomycin ligand as a probe for drug targeting

Conjugates of ovine prolactin and daunomycin were prepared for use as affinity-labelled drug carriers in cancer cells carrying the prolactin receptor. The binding affinity of the conjugates to prolactin receptors in rat liver membrane preparations and in viable granulosa cells derived from estradiol- and pregnant mare serum gonadotropin (PMSG)-treated immature female rats was less than an order of magnitude lower than prolactin. The toxicity of the conjugate in cultured granulosa cells was dependent upon the concentration of the daunomycin present in the culture. The cytotoxic effect of the ligand was abolished by the addition of free prolactin or NH4Cl to the granulosa cell cultures. These conjugates may be useful probes in drug targeting against hormone-sensitive cancer.

Specific non-saturable binding of insulin by human platelets

Studies on the nature and characterization of the specific binding of 125I-insulin to intact human platelets have been undertaken. Although under conditions of physiological buffer osmolality, a binding equilibrium was attained in 4-6 h at 4 degrees C, at higher temperatures (17 degrees C or 24 degrees C) equilibrium was reached only in the presence of very high buffer osmolality or 25 mM NaF. Under conditions of normal osmolality and in the absence of NaF, binding at 17 degrees C was not saturable. This phenomenon was specific for insulin or insulin-like hormones (the insulin-like growth factors) and did not occur with 125I-labelled growth hormone, ACTH or beta-endorphin. The non-saturable uptake of insulin appeared due to an energy-dependent specific sequestration or internalization of insulin by mechanisms probably involving the microtubule system. This study emphasizes the need to restrict this non-saturable uptake of insulin if one wishes to adequately study the platelet plasma membrane receptors for insulin. These data also indicate that there is a major interaction of insulin and insulin-like hormones with normal human platelets and support previous demonstrations of major insulin effects on platelet physiology in both normal and diabetic states.

Lactogenic hormones: binding sites, mammary growth, secretory cell differentiation, and milk biosynthesis in ruminants

Roles of the lactogenic hormones prolactin and placental lactogen in mammary development in ruminants were reviewed. In contrast with other ruminants, failure to detect lactogenic activity in the serum of pregnant cows (in excess of that attributed to prolactin) suggests that placental lactogen may have little direct effect on mammary growth or lactogenesis. However, replacement and ablation experiments using ergocryptine provide definitive evidence that increased periparturient secretion of prolactin is necessary for maximal milk production in cattle. Quantitative microscopy indicates a relative failure of mammary cells in cows with inhibited secretion of prolactin to differentiate structurally. Prolactin induces synthesis and secretion of alpha-lactalbumin in prepartum bovine mammary tissue. Temporary disruption of mammary microtubules immediately prepartum in pregnant heifers reduced subsequent milk production, biosynthetic capacity, and cellular differentiation. For maximal milk production, mammary secretory cells apparently must respond to lactogenic hormone stimulation during the immediate periparturient period. Colchicine may desensitize the mammary epithelium to prolactin action. Membrane binding of radiolabeled human growth hormone to ruminant mammary gland provides a measure of lactogenic hormone binding sites. Specific binding to 600 micrograms of mammary membrane protein was 296% greater in lactating, compared with nonlactating, pregnant (65 days of gestation) ewes. Binding capacity (fmol/mg membrane protein) averaged 275 +/- 57 in mammary membranes from nonlactating, pregnant ewes (100 days gestation, n = 2) and 2,325 +/- 521 in mammary membranes from lactating ewes (n = 6, 14 to 21 days postpartum). Greater understanding of hormonal regulation of the ruminant mammary gland likely will result in development of techniques to produce milk more efficiently and perhaps capability to evaluate production potential of young animals.

Target cell prolactin, II

Is the entry hypothesis compatible with all the existing data about "the" second messenger for prolactin listed in Section II? All of these messengers, in some way either participate in, or modify, prolactin's actions or, in an end point-dependent manner, may actually mimic prolactin. There remains considerable uncertainty as to whether these findings reflect phenomena, some independent of and others quite dependent upon entry, on the one hand, or merely portions of a relatively large number of molecular cascades, some (but not necessarily all) begun initially at the plasmalemma and many (if not all) orchestrated toward completion by intracellular prolactin or agonist-receptor complex.

Prolactin regulation of cryptic prolactin receptors in cultured rat mammary tumor cells

Rat mammary tumors contain a unique class of cryptic cell-surface prolactin receptors that can be unmasked by depleting the cells of energy. These cryptic receptors, which are found in mammary tumors and nonlactating normal mammary cells but not in differentiated mammary tissue, are continuously inserted and rapidly removed from the cell surface. In this report we demonstrate that prolactin regulates the level of cryptic receptors. Treatment of primary cultures of rat mammary tumor cells with prolactin at concentrations between 0.1 and 0.5 ng/ml caused cryptic receptor levels to increase within 24 h, and this increase was maintained for up to 6 days. At prolactin concentrations of 10-50 ng/ml, receptor levels were the same as in cells incubated without hormone, while a decrease in the steady-state level of cryptic receptors was induced within 24 h by 100-500 ng prolactin/ml. Concentrations of 1,000-5,000 ng prolactin/ml caused a rapid, dose-dependent down regulation of cryptic receptor sites. Down regulation at 5,000 ng prolactin/ml was (1) complete (84 +/- 5% reduction) in 1 h; (2) specific for lactogenic hormones; (3) completely reversed within 10 h after prolactin removal; (4) energy dependent; and (5) not blocked by the cytoskeleton active agents cytochalasin B and colchicine or by NH4Cl, which inhibits hormone degradation. We conclude that rat mammary tumor cells have the capacity to auto-regulate cryptic prolactin receptors, a property that supports our notion that such receptors play a role in regulating prolactin responsiveness. The observed pattern of cryptic receptor autoregulation in response to prolactin concentration and time of exposure suggests that a pool of cryptic sites provides these cells with the capacity to respond to prolactin concentrations from pg to microgram/ml, a range well beyond the Kd for the receptor itself. Since prolactin receptors in mammary tumors are not down regulated unless prolactin concentrations are well beyond the saturation point, these cells may have a selective growth advantage over cells in normal mammary tissue.

Characterization of antisera to a partially purified prolactin receptor: effect on prolactin binding in different target tissues

Prolactin (PRL) receptors have been purified by affinity chromatography using a lactogenic hormone (human growth hormone, hGH) coupled to Affigel-10. The mean binding capacity of 3 separate purifications was 1.18 +/- 0.26 nmoles prolactin per mg protein, representing a 836-fold purification over crude microsomes and 4000-5000-fold over mammary gland homogenates and 16% purity. The receptor was characterized by HPLC using a TSK-SW-4000 and 3000 column connected in series and eluted in 0.1 M borate buffer containing 0.2 M NaCl and 0.1% Triton. A single peak of [125I]hGH binding activity with a retention time of 45.2 min (22.6 ml), representing an apparent molecular weight of 133000, was observed. A single peak of activity was also observed following polyacrylamide gel electrophoresis of the purified receptor in 0.1% Triton coincident with the Coomassie-stained protein band. Antibodies to the partially purified receptor preparations were prepared in sheep, goats and guinea pigs. Antisera to the prolactin receptor prepared in all three species were capable of inhibiting the binding of 125I-labeled ovine prolactin to receptors from rabbit mammary glands. Significant inhibition of binding was observed at antisera dilution of 1:10 000 with the sheep antiserum being the most potent (half-maximal inhibition (IM50) = 1:5700). All three antisera were able to inhibit PRL binding completely, but failed to affect labeled insulin or hCG binding and had very little effect on bGH binding. The specificity of the sheep antiserum was tested in rabbit mammary glands, ovary, adrenal, pig mammary glands and 8 rat tissues which contain PRL receptors. The antiserum was able to inhibit the binding of labeled PRL in all tissues, with the inhibition curves for the rat tissues being non-parallel when compared to rabbit mammary gland, suggesting a homology but not a complete identity between PRl receptors in various tissues and animal species. These studies demonstrate that prolactin receptors can be purified from rabbit mammary tissue and that antisera can be produced in several species. In addition, the binding studies suggest that in the various tissues the receptor molecule is more or less exposed to interaction with the antisera, or that the receptor protein differs somewhat between species.

Down-regulation of prolactin receptors in the liver, mammary gland and kidney of female virgin rat, infused with ovine prolactin or human growth hormone

Down regulation of prolactin (PRL) receptors resulting from i.v. infusion of oPRL or human growth hormone (hGH) into female virgin rats was demonstrated. A decrease of over 85% in the number of free receptors was achieved within 15 - 30 min using infusion of oPRL or hGH at 25 micrograms/h and remained at this level until the end of infusion. Ovine growth hormone or recombinant bovine growth hormone at ten-fold higher concentration had no effect at all. The decrease in the specific binding resulted from a lower number of binding sites and not from change in the dissociation constants. The decrease in the total receptors in the liver was more gradual and leveled off at 40 - 50% of the initial value. Our results suggest that a change in blood PRL or hGH level may lead to a new steady state in the number, occupancy and distribution of prolactin receptors.

Effects of transglutaminase or phospholipase A2 inhibitors on down-regulation of prolactin receptors and stimulation of casein and DNA synthesis in mammary gland explants

A number of compounds have been found to inhibit the internalization of alpha 2-macroglobulin and/or epidermal growth factor into fibroblasts. Using the same inhibitor we tried to block the down-regulation of prolactin receptors, supposed to mirror internalization of PRL receptors, in order to investigate the possible role of internalization in the mechanism of prolactin action. In rabbit mammary cells it appeared that bacitracin and ethylamine completely block prolactin receptor down-regulation, but dansylcadaverine, the most potent inhibitor of transglutaminase, was without effect. The blockage of phospholipase A2 by chlorpromazine or bromophenacyl bromide (BPB) was without effect on the down-regulation of prolactin receptor. Subcellular distribution of [125I]oPRL has been studied after incubation with or without these various inhibitors after fractionation of mammary gland homogenate on sucrose gradient. Any of these compounds was able to increase the labelling of prolactin receptors located in plasma membrane fractions, suggesting that the rate of internalization of prolactin was not modified. In addition, none of these compounds inhibited the stimulation of beta-casein and DNA synthesis by prolactin. These results suggest that both transglutaminase and phospholipase A2 are not involved in the mechanism of prolactin-induced down-regulation of prolactin receptors, although bacitracin and ethylamine are able to block this phenomenon probably by different mechanism. In all cases, inductions of mitogenesis and beta-casein synthesis by prolactin in the rabbit mammary cells were not modified by the various compounds utilized. We conclude that neither transglutaminase nor phospholipase A2 are involved in the internalization of prolactin-receptor complexes, although bacitracin, ethylamine and quinacrine are able to block the down regulation of prolactin receptors by other means.

Comparative measurement of the lactogenic activity of ovine placental lactogen in rabbit and ewe mammary gland

Ovine placental lactogen is known to bind to prolactin receptors and to initiate milk synthesis in the rabbit mammary gland. However, this hormone exhibited a very low capacity of competing with 125I-labeled human growth hormone for the binding to membranes extracted from ewe mammary gland. Ovine placental lactogen was very efficient in provoking the accumulation of beta-casein mRNA in rabbit mammary explants but was much less active on ewe mammary explants. These data indicate that the placental hormone is not a potent lactogen in the homologous species and that its role in the control of mammary gland development and activity may have been previously overestimated.

Prolactin receptors in explant cultures of carcinogen-induced rat mammary tumors

The turnover, down-regulation and role of intracellular organelles in the down-regulation of prolactin (PRL) receptors have been investigated in N-nitrosomethylurea (NMU)-induced rat mammary tumors cultured in short-term explants. Tumor explants are capable of maintaining PRL receptors for 24-48 hr. This maintenance reflects a dynamic phenomenon involving receptor synthesis, since addition of cycloheximide (1 microgram/ml) in the culture medium results within 12 hr in a marked decline of PRL receptor levels. A down-regulation of total PRL receptors (measured after exposure of membranes to 3M MgCl2) is observed in cultures containing concentrations of 20 micrograms/ml or greater of ovine PRL (oPRL). Lysosomotropic agents, such as chloroquine (100 microM) are ineffective in either increasing basal PRL receptor levels or in preventing the PRL-induced down-regulation in NMU-induced mammary tumor explants. Cytochalasin B (20 microM), without effect on basal PRL binding, prevents the down-regulation of PRL receptors, whereas colchicine (10 microM) results in a decline of PRL receptor levels both in the absence and in the presence of oPRL. The present data suggest a different pattern of PRL receptor regulation in vitro for tumors compared to normal rabbit mammary explants.

Uptake and degradation of desialylated luteinizing hormone by suspended hepatocytes

The uptake and degradation of desialylated human luteinizing hormone (asialo-LH) in suspended hepatocytes have been studied. Asialo-LH was taken up by the asialo-glycoprotein receptor at a rate which was somewhat lower than that of asialo-fetuin. The rate constants and equilibrium binding parameters were similar, but the rate of dissociation of the receptor-ligand complex was higher in the case of asialo-LH. The uptake was influenced by heterogeneity of the asialo-LH preparation. Degradation of endocytosed asialo-LH took place in the lysosomes. After fractionation of the cells by isopycnic centrifugation in a sucrose gradient, partially degraded asialo-LH (precipitable with trichloracetic acid, but not with antibody) was found in the fractions containing endocytic vesicles, but not in the lysosomal fractions, indicating that the proteolysis of asialo-LH was initiated in the endocytic vesicles.

Prolactin receptor turnover in explants of pseudopregnant rabbit mammary gland

Pseudopregnant rabbit mammary glands in organ culture were used to investigate prolactin (PRL) receptor turnover. Chloroquine (100 microM) results in an increase in prolactin receptor levels (15.7 +/- 1.2% to 35.9 +/- 3.5% specific binding), whereas cycloheximide (1 microgram/ml) induces a rapid decline (to 6.4 +/- 1.2%) suggesting a rapid synthesis and degradation of the receptor molecule. Inhibitors of cellular transcription have little effect on receptor levels. Neither actinomycin D nor dichlororibofuranosylbenzimidazole (DRB) diminish PRL receptor levels whereas total protein synthesis is almost completely inhibited, and chloroquine increases the binding even in the presence of transcriptional inhibitors. These results imply that receptor synthesis continues and that the mRNA for the receptor protein is particularly stable. Ouabain (3 micrometers), which blocks the ATP-dependent Na+/K+ pump, provokes a greater than 60% reduction in PRL receptor levels without modifying total protein synthesis. Dinitrophenol (DNP, 1 mM), an oxidative uncoupler, has little effect on receptor levels, possibly due to a blockage of both synthesis and degradation. Prolactin is capable of inducing a 60% down-regulation of its own receptor, and this phenomenon appears to be energy-dependent because it is partially inhibited by DNP. This process seems to involve an increased rate of receptor degradation. These studies suggest that, at any one time, the level of PRL receptors in a target cell is the result of a dynamic equilibrium between receptor synthesis and degradation and that the most frequent modulations occur at the level of translation and lysosomal degradation. In conclusion, in mammary glands of the pseudopregnant rabbit, the prolactin receptor molecule appears to have a short half-life; the mRNA for this protein, however, is relatively stable.

[Role of membrane colchicine binding proteins in the transmission of prolactin message to casein genes in the rabbit mammary gland]

Previous work demonstrated that tubulin binding drugs specifically inhibit the capacity of prolactin to initiate casein and DNA synthesis in the mammary cell. It was concluded that microtubules or other tubulin containing cellular structures were involved in the transmission of the prolactin message to genes. In the present work, it is shown that griseofulvin, an antimitotic drug which alters microtubule structure and function, does not prevent prolactin actions. Autoradiographic studies showed that [3H]colchicine binds preferentially to plasma and Golgi membranes in the mammary cell. Short term cultures of mammary explants with [3H]colchicine demonstrated that the labelled drug binds to membranous cellular structures which were isolated from explants at the end of the culture. Fractions containing plasma and Golgi membranes contained the highest amount of radioactivity. Solubilisation of the membranes by Triton X-100 dissociated the [3H]colchicine from the prolactin receptors as judged by a chromatography of the soluble fraction on a Sepharose 6 B column. On the column, the labelled colchicine remains associated with a molecular entity which may be free tubulin. In all cases, the binding of [3H]colchicine was greatly attenuated by an excess of unlabelled colchicine but was only slightly affected by the competition with lumicolchicine. These results suggest that mammary membranes contain tubulin and that binding of drugs to this molecule inhibits the generation of the prolactin second messengers eliciting the hormonal actions in the mammary cell. This also suggests that microtubules are probably not involved in the mechanism of prolactin action.

Induction of casein synthesis by prolactin and inhibition by progesterone in the pseudopregnant rabbit treated by colchicine without any simultaneous variations of casein mRNA concentration

Prolactin injected into pseudopregnant rabbits induced casein synthesis and it provoked an accumulation of casein mRNA and of ribosomal RNA. Colchicine, which has been shown to block the prolactin signal, totally prevented the accumulation of beta-casein mRNA, when injected with the hormone. However, the drug did not hamper the initiation of casein synthesis and the accumulation of ribosomal RNA. The effect of prolactin injected with colchicine on casein synthesis was totally abrogated by progesterone administered simultaneously and it was essentially unmodified by glucocorticoids. These results suggest that prolactin controls casein gene expression by supporting the accumulation of casein mRNAs and by stimulating the translation of these mRNAs, through independent mechanisms. Progesterone which is known to prevent the accumulation of casein mRNAs is also a potent inhibitor of casein mRNA translation whereas glucocorticoids exert their effect essentially by favouring the accumulation of casein mRNA but not by modifying their translation efficiency.